Peter Ambrosini - SPDR SP Chief Compliance Officer
| XPH Etf | USD 44.42 0.28 0.63% |
Peter A. Ambrosini is Senior Principle Chief Compliance Risk Management Officer, SSgA Funds Management, Inc. Managing Director, PricewaterhouseCoopers .
| Age | 68 |
| Tenure | 21 years |
| Issuer | SSgA |
| Inception Date | 2006-06-19 |
| Benchmark | S&P Pharmaceuticals Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 165.13 Million |
| Average Trading Valume | 44,116.3 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
Similar Fund Executives
| Showing other executives | One Year Return | ||
| Donald Wilson | Invesco Dynamic Pharmaceuticals | 54 | |
| Keith Ovitt | Invesco Dynamic Pharmaceuticals | 49 | |
| Helen Peters | SPDR SP Oil | 71 | |
| Robert Kapito | iShares Pharmaceuticals ETF | 62 | |
| Cecilia Herbert | iShares Pharmaceuticals ETF | 67 | |
| Kevin Gustafson | Invesco Dynamic Pharmaceuticals | 42 | |
| Mary Zeven | SPDR SP Oil | 51 | |
| Madhav Rajan | iShares Pharmaceuticals ETF | 52 | |
| John Kerrigan | iShares Pharmaceuticals ETF | 60 | |
| Chad Hallett | SPDR SP Oil | 46 | |
| John Martinez | iShares Pharmaceuticals ETF | 55 | |
| Gary French | SPDR SP Oil | 67 | |
| Eilleen Clavere | iShares Pharmaceuticals ETF | 60 | |
| Matthew Flaherty | SPDR SP Oil | 41 | |
| John Clark | SPDR SP Oil | 45 | |
| Scott Zoltowski | SPDR SP Oil | 43 | |
| Philip Nussbaum | Invesco Dynamic Pharmaceuticals | 51 | |
| Ronn Bagge | Invesco Dynamic Pharmaceuticals | 54 | |
| Robert Silver | iShares Pharmaceuticals ETF | 57 | |
| Frank Nesvet | SPDR SP Oil | 68 | |
| Marc Kole | Invesco Dynamic Pharmaceuticals | 52 | |
SPDR SP Pharmaceuticals Money Managers
| Gary French, Treasurer | ||
| John Clark, Assistant Treasurer | ||
| Dave Kelly, Independent Trustee | ||
| Helen Peters, Independent Trustee | ||
| Matthew Flaherty, Assistant Treasurer | ||
| Michael Riley, Vice President | ||
| Mary Zeven, Secretary | ||
| Chad Hallett, Assistant Treasurer of Street tracks series trust | ||
| Scott Zoltowski, Assistant Secretary | ||
| Peter Ambrosini, Chief Compliance Officer | ||
| James Ross, President Trustee | ||
| Frank Nesvet, Independent Trustee |
SPDR Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is SPDR SP a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 6.56 X | |||
| Price To Book | 1.51 X | |||
| Price To Sales | 2.83 X | |||
| Gross Profit | 2.66 M | |||
| Earnings Per Share | (11.87) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.73 | |||
| Market Capitalization | 236.07 M | |||
| Total Asset | 206.63 M | |||
| One Year Return | 6.90 % |
Currently Active Assets on Macroaxis
When determining whether SPDR SP Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SPDR SP's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spdr Sp Pharmaceuticals Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Spdr Sp Pharmaceuticals Etf:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in SPDR SP Pharmaceuticals. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
The market value of SPDR SP Pharmaceuticals is measured differently than its book value, which is the value of SPDR that is recorded on the company's balance sheet. Investors also form their own opinion of SPDR SP's value that differs from its market value or its book value, called intrinsic value, which is SPDR SP's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SPDR SP's market value can be influenced by many factors that don't directly affect SPDR SP's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SPDR SP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SPDR SP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SPDR SP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.